A vaccine designed to intercept pancreatic cancer before it starts has passed its first real-world test. Researchers reported that a first-in-human KRAS-targeted vaccine safely triggered durable T-cell responses in 90% of high-risk participants — and after a median follow-up of 16.5 months, none developed pancreatic cancer. Several precancerous lesions even shrank or stopped growing. Published in Cancer Discovery, the study is the first proof of concept that a...